Printed arrays |
In-house manufacture by a core facility NimbleGen (Roche) Agilent |
|
-
•
Need reliable access to a core facility(dust, humidity and temperature controlled)
-
•
Little supervision over quality control of manufacture
-
•
Requires extensive in-house probe design and manufacture
-
•
Requires expensive assay validation
-
•
Requires access to in-house bioinformatics to analyze and assess quality of the data
-
•
Can be inflexibility to change assay probes as required
-
•
Can be non-conducive to user-defined development (exception: Agilent)
|
In-situ synthesized oligonucleotide arrays |
GeneChip®(Affymetrix) |
-
•
Custom-assay production
-
•
Automated
|
-
•
Most expensive
-
•
High-density so (15,000 to >106) spot probes per assay
-
•
Complex to manufacture – probes chemically synthesized directly on quartz wafers
|
Electronic |
NanoChip® (Nanogen) |
-
•
Electric fields promote active hybridization to nucleic acids onto a microelectronic device
-
•
Low-density (400 maximum) but adequate for diagnostic panel assays
-
•
Less expensive than high-density format
-
•
Allows flexible testing of multiple targets in a single sample or multiple samples on the same microarray cartridge
|
|
Liquid-based suspension bead-based arrays |
Luminex Molecular Diagnostics |
-
•
Probes or universal sequence tags are attached to spectrally unique microspheres; bead hybridization with fluorescently labeled target DNA measured by flow cytometry
-
•
Low-density (100 maximum) but adequate for diagnostic panel assays
-
•
Less expensive than high-density format
-
•
Only FDA-approved commercial assay (xTAG Respiratory Panel)
-
•
Most flexible, practical format for clinical use
-
•
Multitude of clinical applications
|
|